DDInter742 DDInter1376
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Floxuridine {u} (Compound) resembles {v} (Compound) Trifluridine
Floxuridine {u} (Compound) resembles {v} (Compound) Emtricitabine
Floxuridine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Floxuridine {u} (Compound) treats {v} (Disease) stomach cancer
Floxuridine {u} (Compound) binds {v} (Gene) TYMS
Floxuridine {u} (Compound) upregulates {v} (Gene) PMAIP1
Floxuridine {u} (Compound) is included by {v} (Pharmacologic Class) Deoxyuridine
Floxuridine {u} (Compound) downregulates {v} (Gene) PPP2R3C
Floxuridine {u} (Compound) causes {v} (Side Effect) Myocardial ischaemia
Floxuridine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Floxuridine (Compound) resembles Trifluridine (Compound)
Floxuridine (Compound) resembles Emtricitabine (Compound)
Floxuridine may lead to a major life threatening interaction when taken with Cladribine
Floxuridine (Compound) treats stomach cancer (Disease)
Floxuridine (Compound) binds TYMS (Gene)
Floxuridine (Compound) upregulates PMAIP1 (Gene)
Floxuridine (Compound) is included by Deoxyuridine (Pharmacologic Class)
Floxuridine (Compound) downregulates PPP2R3C (Gene)
Floxuridine (Compound) causes Myocardial ischaemia (Side Effect)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin